The Clinical Pharmacology Analytical Core (CPAC) assists Indiana University Simon Cancer Center (IUSCC) investigators in support of research projects and scientific goals, CPAC has been in existence since September 2004 and is the only laboratory on campus that provides investigators state-of-the-art technology to quantify small molecules, drugs, and metabolites, to identify compounds based on their mass spectra, and to analyze pharmacokinetic data. Access to state-of-the-art instrumentation for quantification of drugs and metabolites is an invaluable resource for all cancer investigators in the IUSCC. The CPAC develops and performs assays to identify and/or quantify drugs and metabolites from in vitro (including tissue extracts, cell culture and cell extracts) and in vivo studies (including humans or other animals). It also conducts pharmacokinetic analyses that describe drug (or metabolite) concentrations in the body over a period of time, from absorption to excretion, and information on drug exposure. These services ultimately assist investigators in the analysis of their research protocols regarding pharmacokinetics, pharamacodynamics, pharmacogenetics, toxicity, tumor response and identification of appropriate individualized therapies. This technology has allowed IUSCC investigators to make critical pharmacogenetic observations that are already impacting patient care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA082709-14S3
Application #
8637214
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-09-22
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
14
Fiscal Year
2013
Total Cost
$82,641
Indirect Cost
$29,666
Name
Indiana University-Purdue University at Indianapolis
Department
Type
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Reese, Michael J; Knapp, Deborah W; Anderson, Kimberly M et al. (2018) In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs. PLoS One 13:e0203517
Singh, Pratibha; Fukuda, Seiji; Liu, Liqiong et al. (2018) Survivin Is Required for Mouse and Human Bone Marrow Mesenchymal Stromal Cell Function. Stem Cells 36:123-129
Olivos 3rd, David J; Perrien, Daniel S; Hooker, Adam et al. (2018) The proto-oncogene function of Mdm2 in bone. J Cell Biochem 119:8830-8840
Shiue, Kevin; Cerra-Franco, Alberto; Shapiro, Ronald et al. (2018) Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy. J Thorac Oncol 13:1549-1559
Liu, Yunhua; Xu, Hanchen; Van der Jeught, Kevin et al. (2018) Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer. J Clin Invest 128:2951-2965
Pin, Fabrizio; Barreto, Rafael; Kitase, Yukiko et al. (2018) Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle 9:685-700
Robertson, Michael J; Stamatkin, Christopher W; Pelloso, David et al. (2018) A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma. J Immunother 41:151-157
Huang, Xinxin; Guo, Bin; Liu, Sheng et al. (2018) Neutralizing negative epigenetic regulation by HDAC5 enhances human haematopoietic stem cell homing and engraftment. Nat Commun 9:2741
Serratore, Nina D; Baker, Kortany M; Macadlo, Lauren A et al. (2018) A Novel Sterol-Signaling Pathway Governs Azole Antifungal Drug Resistance and Hypoxic Gene Repression in Saccharomyces cerevisiae. Genetics 208:1037-1055
Hoggatt, Jonathan; Singh, Pratibha; Tate, Tiffany A et al. (2018) Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell. Cell 172:191-204.e10

Showing the most recent 10 out of 256 publications